Company
Shield Therapeutics plc
Headquarters: Gateshead, United Kingdom
Employees: 15
CEO: Mr. Gregory P. Madison
Market Cap
£24.9 Million
GBP as of Jan. 1, 2025
US$31.2 Million
Shield Therapeutics plc Categories
United Kingdom Healthcare Drug Manufacturers—Specialty & GenericUnited Kingdom Healthcare United Kingdom Drug Manufacturers—Specialty & Generic
Top Competitors by Market Capitalization
Industry: Drug Manufacturers—Specialty & Generic
Sector:
| Company | Market Cap (USD) |
|---|---|
| Lilly | $689.42 B |
| Novo Nordisk | $622.07 B |
| UnitedHealth Group | $487.54 B |
| Johnson & Johnson | $353.05 B |
| AbbVie | $301.60 B |
Detailed Description
Shield Therapeutics plc, a specialty pharmaceutical company, engages in the development and commercialization of late-stage pharmaceuticals to treat unmet medical needs. The company's lead product is Ferric Maltol, marketed in the European Union as Feraccru, a non-salt based oral therapy for the treatment of iron deficiency with or without anaemia in adults. It also develops PT20, a novel therapy that has completed its Phase II pivotal study for the treatment of hyperphosphatemia in patients with chronic kidney disease; PT30 to treat hypo-allergenic IV iron therapy; and PT40, the first generic version of iron sucrose. The company was founded in 2008 and is based in Gateshead, the United Kingdom.
Financials
| Last Financial Reports Date | June 30, 2023 |
| Revenue TTM | £5.9 M |
| EBITDA | £-22,513,607 |
| Gross Profit TTM | £2.0 M |
| Profit Margin | 44.71% |
| Operating Margin | -266.29% |
| Quarterly Revenue Growth | 65.80% |
Stocks & Indices
Shield Therapeutics plc has the following listings and related stock indices.
Stock: LSE: STX wb_incandescent
Stock: FSX: 1JS wb_incandescent
Stock: OTC: SHIEF wb_incandescent